{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:35:06Z","timestamp":1761845706653,"version":"build-2065373602"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000805","name":"European Centre for Disease Prevention and Control","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000805","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 breakthrough cases raised crucial questions about vaccine effectiveness, implications for public health, and the dynamics of viral transmission. We described vaccine breakthrough infections in Tirana during the Delta (01\/07\/2021-12\/15\/2021) and Omicron (16\/12\/2021\u201331\/03\/2022) periods, to better inform mitigation and vaccination strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extracted data from 01\/04\/2021\u201331\/03\/2022 (study period) from two systems: the Albanian infectious disease surveillance system, and the national vaccination database. We defined a COVID-19 case as a resident of Tirana who tested (RT-PCR\/antigen) positive for SARS-CoV-2 on a respiratory specimen. We defined vaccine breakthrough infection as having a COVID-19 positive specimen collected \u226514 days after the primary series of vaccines (2 doses). We calculated risk of breakthrough infection using the total number of fully vaccinated individuals as denominator and risk ratios (RR) using binomial regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, 23,875 cases were reported in Tirana; 36% (291,445\/800,000) individuals were fully vaccinated and among those, 9,156 (3.1%) breakthrough infections were detected. The median time from vaccination to breakthrough infection was 149 (IQR:102\u2013209) days. The risk of breakthrough infection was higher in 0\u201339-year-olds (RR\u2009=\u20093.01;95%CI\u2009=\u20092.78\u20133.27) and during the Omicron period (RR\u2009=\u200932; 95%CI\u2009=\u200930.00\u201334.91). Those receiving Gam-COVID ((RR\u2009=\u20091.64;95%CI\u2009=\u20091.39\u20132.02), ChAdOx1-S\/Vaxzervria (RR\u2009=\u20091.56;95%CI\u2009=\u20091.48\u20131.65), or BNT162b2-Comirnaty (RR\u2009=\u20091.36;95%CI\u2009=\u20091.31\u20131.41) had a higher risk of breakthrough infection compared with those vaccinated with CoronaVac.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Incidence of COVID-19 breakthrough infection was significantly higher during the Omicron period and among younger individuals in Tirana. The substantially elevated risk associated with Omicron variant breakthrough infection and the decline in infection protection after a 5-month period, warrants close monitoring and rapid adaptation of vaccination strategies, including promoting booster vaccination to reduce breakthrough infections in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0335197","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:24:16Z","timestamp":1761845056000},"page":"e0335197","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 breakthrough infections during the circulation of Delta and Omicron variants in Tirana, Albania, April 2021\u2013March 2022"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5611-3488","authenticated-orcid":true,"given":"Fiona","family":"Konomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-3373","authenticated-orcid":true,"given":"Kujtim","family":"Mersini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7701-1902","authenticated-orcid":true,"given":"Arlinda","family":"Ramaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Danis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"pone.0335197.ref001","article-title":"A comprehensive status report","author":"SP GuptaKaur","journal-title":"Simran Preet Kaur and Vandana"},{"key":"pone.0335197.ref002","volume-title":"COVID-19 vaccines","author":"Food and Drug Administration","year":"2021"},{"issue":"20","key":"pone.0335197.ref003","doi-asserted-by":"crossref","first-page":"753","DOI":"10.15585\/mmwr.mm7020e2","article-title":"Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel - 33 U.S. sites, January-March 2021","volume":"70","author":"T Pilishvili","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0335197.ref004","doi-asserted-by":"crossref","unstructured":"Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status \u2014 New York, May 3\u2013July 25, 2021. 2021.","DOI":"10.15585\/mmwr.mm7034e1"},{"key":"pone.0335197.ref005","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","author":"LR Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0335197.ref006","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19","volume":"384","author":"J Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0335197.ref007","unstructured":"Uschner D, Bott M, Lagarde WH, Keating J, Tapp H, Berry AA, et al. Breakthrough SARS-CoV-2 infections after vaccination in North Carolina."},{"key":"pone.0335197.ref008","unstructured":"DeSantis SM, Yaseen A, Hao T, Le\u00f3n-Novelo L, Talebi Y, Valerio-Shewmaker MA, et al. Incidence and predictors of breakthrough and severe breakthrough infections of SARS-CoV-2 after primary series vaccination in adults: a population-based survey of 22 575."},{"issue":"4","key":"pone.0335197.ref009","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"MG Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0335197.ref010","unstructured":"Yamal J-M, Appana S, Wang M, Leon-Novelo L, Bakota E, Ye Y, et al. Trends and correlates of breakthrough infections with SARS-CoV-2."},{"key":"pone.0335197.ref011","unstructured":"Jing X, Han M, Wang X, Zhou L. SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review."},{"key":"pone.0335197.ref012","unstructured":"Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, et al. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era."},{"key":"pone.0335197.ref013","unstructured":"Kaur U, Bala S, Ojha B, Pathak BK, Joshi A, Yadav AK, et al. Determinants of COVID-19 breakthrough infections and severity in ChAdOx1 nCoV-19\u2013vaccinated priority groups."},{"key":"pone.0335197.ref014","unstructured":"Yi S, Choe YJ, Kim J, Kim Y-Y, Kim RK, Jang EJ, et al. SARS-CoV-2 breakthrough infections after introduction of 4 COVID-19 vaccines, South Korea, 2021."},{"key":"pone.0335197.ref015","unstructured":"Moosa AS, Wee YMS, Jaw MH, Tan QF, Tse WLD, Loke CY, et al. A multidisciplinary effort to increase COVID-19 vaccination among the older adults."},{"key":"pone.0335197.ref016","unstructured":"Fiolet T, Kherabi Y, MacDonald C o n o r-J a m e s, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review."},{"key":"pone.0335197.ref017","unstructured":"Wei Y, Jia KM, Zhao S, Hung CT, Mok CKP, Poon PKM, et al. Estimation of vaccine effectiveness of CoronaVac and BNT162b2 against severe outcomes over time among patients with SARS-CoV-2 Omicron."},{"key":"pone.0335197.ref018","unstructured":"Ben Fredj S, Ghammem R, Zammit N, Maatouk A, Haddad N, Haddad N, et al. Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study."}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:24:19Z","timestamp":1761845059000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335197"}},"subtitle":[],"editor":[{"given":"Geetika","family":"Verma,","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0335197","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}